GlassScriptPhysician profile
Karen Muro
NPI 1750359188
$2,090.39
in general payments reported to CMS, 2019-2025
23 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $95.62 · 2021: $224 · 2022: $365 · 2023: $574 · 2024: $380 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,149 · Education: $93.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.02 |
| Education | $93.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $235.71 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $202.08 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $185.02 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $181.28 | 2019-2024 | Velphoro |
| Amgen INC. | $153.81 | 2020-2023 | Tavneos, Parsabiv |
| Aurinia Pharma U.S., INC. | $147.02 | 2021-2025 | Lupkynis |
| Outset Medical INC | $125.00 | 2023 | |
| Vifor Pharma, INC. | $118.24 | 2019-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $116.31 | 2021-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $91.31 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $76.61 | 2019-2024 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $69.63 | 2022-2023 | Acthar |
| Ardelyx, INC. | $61.61 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $52.83 | 2021-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $52.79 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $51.46 | 2022-2025 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $39.08 | 2021-2022 | |
| Lilly USA, LLC | $24.88 | 2025 | Jardiance |
| Genzyme Corporation | $23.86 | 2022 | |
| Akebia Therapeutics INC | $23.85 | 2022 | |
| Apellis Pharmaceuticals, INC. | $21.66 | 2025 | Empaveli |
| Mallinckrodt Enterprises LLC | $19.26 | 2019 | |
| Lemaitre Vascular, INC. | $17.09 | 2024 | Artegraft Vascular Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Muro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.